VYALEV® is now available on the PBS for advanced Parkinson’s.
From 1 August 2025, Australians living with advanced Parkinson’s will have access to a new treatment option — VYALEV®, a 24-hour levodopa-based infusion therapy delivered subcutaneously via a wearable pump.
This is a major step forward in improving quality of life for those experiencing severe motor fluctuations and we’re proud to have advocated for this breakthrough.
Parkinson’s Australia has advocated for access to VYALEV® in Australia to ensure people living with advanced Parkinson’s have a wider choice of treatments that can help improve daily living. Throughout this process consumer voices have been vital in helping decision makers understand the impacts of living with Parkinson’s. We are delighted the Australian Government has made this treatment affordable and available for the Parkinson’s community.
— Olivia Nassaris, CEO Parkinson’s Australia
We’ve worked tirelessly to ensure consumer voices were heard. Your stories helped decision-makers understand the real impact of Parkinson’s — and why access to VYALEV® matters.
After being housebound for five years I’ve regained my mobility and independence. I hope the listing of this treatment will provide other Australians the same chance to regain quality of life.
Paula – living with Young Onset for over 30 years & on the VYALEV® trial
Oral medications have begun to lose their efficacy for me. I have lots of on and off periods. This new treatment will mean I can be a better dad, a better husband and stay in the workforce longer.
Craig – living with Young Onset
Why this matters
Parkinson’s affects over 150,000 Australians, with someone diagnosed every 27 minutes.
It’s the fastest-growing neurological condition in the world — and it doesn’t just affect older people.
- 10% are diagnosed under 45
- 18% are of working age
Advanced Parkinson’s brings serious challenges: motor fluctuations, falls, dyskinesia, and loss of independence. VYALEV® offers a new option for those who are no longer responding to other treatments.
What is VYALEV®?
VYALEV® (foslevodopa with foscarbidopa) is a 24-hour infusion therapy for advanced idiopathic Parkinson’s.
- Administered under the skin via a pump
- Designed for continuous symptom control
- Now subsidised through the PBS!
For people with severe motor fluctuations, this therapy can mean fewer interruptions, more stability, and better daily functioning.
What’s next?
We celebrate this milestone — but our work continues. We’ll keep advocating for:
- Earlier diagnosis
- Better support for carers
- More treatment options
- Greater awareness.
More:
Australian Public Assessment Report
Parkinson’s Australia Media Release
Contact for interviews: Olivia Nassaris | Parkinson’s Australia CEO 0478 913 214 | olivia@parkinsons.org.au
